首页 > 市场调查报告书 > 医疗设备

心血管设备

市场调查报告书

商品编码

1319139

全球心血管假体设备市场 - 2023-2030 年

Global Cardiovascular Prosthetic Device Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

2022 年，全球心血管假体设备市场规模达到 153 亿美元，预计到 2030 年将达到 289 亿美元，2023-2030 年的年复合增长率为 8.4%。

心血管假体设备可模仿人体心脏部件的功能。这些装置被替换到人体中，以修复故障或修复受损的瓣膜或组织。心脏假体的设计目的是通过保持单向血流来复制原生瓣膜的功能，而且所使用的材料必须是抗凝血的，尽管它是有生命的。

心血管假体设备是可植入或外置的设备，用于替代或辅助心血管系统的各个部分，如心脏、动脉或静脉。心脏修复装置可提高大多数患者的生存率，并显著提高生活质量。雅培实验室、波士顿科学公司、美敦力公司等主要企业都在积极开拓这一市场。

市场动态

心力衰竭发病率上升推动市场增长

心力衰竭发病率的增加在促进市场增长方面发挥了重要作用。许多人患有心脏中风和心力衰竭，这提高了植入率。心力衰竭是影响许多人的主要问题。例如，据美国心力衰竭协会统计，每年新增心力衰竭病例96万例。每年约有 3770 万人住院治疗。因此，心衰患者发病率的增加正在扩大市场增长。

老年人口的增加推动了市场增长

老年人口发病率的增加推动了市场的增长。老龄化是影响心脏正常功能的主要因素之一。随着年龄的增长，心脏功能会受到不利影响。衰老会导致心脏和血管发生变化。

例如，据美国心脏协会期刊估计，70 岁以上的人中有 70% 会患上心血管疾病。据报道，在 45 岁及以上的成年人中，有 14.2% 的人患有冠心病、中风或同时患有这两种疾病。因此，老年人口数量的增加将扩大市场增长。

植入治疗的高成本将阻碍市场增长

植入治疗的高成本会阻碍市场增长。由于手术的复杂性增加，与植入相关的手术治疗费用也随之增加。例如，美国心脏起搏器手术的平均费用在 2,000 美元至 2,500 美元之间。

COVID-19 影响分析

COVID-19 大流行对心血管修复装置产生了重大影响，给许多国家带来了前所未有的挑战。外科手术的延迟和推迟，以及病人对医院的恐惧，都对心血管修复装置的使用产生了影响。这导致在 COVID-19 大流行期间，心血管修复装置的增长大幅下降。

俄乌战争影响分析

据估计，俄乌冲突对心血管假体设备的影响不大，因为该地区的主要市场参与者较少。不过，原材料进出口的影响预计在预测期内对心血管修复装置的增长影响不大。

Market Overview

Global Cardiovascular Prosthetic Device Market reached US$ 15.3 billion in 2022 and is expected to reach US$ 28.9 billion by 2030 growing with a CAGR of 8.4% during the forecast period 2023-2030.

A cardiovascular prosthetic device mimics the functions of the parts of the human heart. These devices are replaced in the human body in order to repair the malfunction or to repair the damaged valves or tissues. The cardiac prosthesis is designed to replicate the function of native valves by maintaining unidirectional blood flow, and the material that is used should be anticoagulant although life.

Cardiovascular prosthetic devices are implantable or external devices that replace or assist parts of the cardiovascular system, such as the heart, arteries, or veins. Prosthetic cardiac devices improve survival and significantly increase the quality of life in most patients. Significant key players like Abbott Laboratories, Boston Scientific, Medtronic, among others are actively operating in the market.

Market Dynamics

An Increase in the Incidence of Heart Failure is Boosting the Market Growth

An increase in the incidence of heart failure is playing a major role in boosting market growth. A large number of people are suffering from heart strokes and heart failure,which is increasing the rate of implantations. Heart failure is a major problem affecting many people. For instance, according tothe Heart Failure Society of America, 960,000 new heart failure cases annually. About 37.7 million people are hospitalized each year. Thus, the increase in the incidence of heart failure patients is expanding the market growth.

An Increase in the Geriatric Population is Fueling the Market Growth

The increase in the incidence of the geriatric populationis fueling the growth of the market. Aging is one of the major factors which shows the influence on the functioning of the heart properly. Heart function gets adversely affected as age increases. Aging can cause changes in the heart and blood vessels.

For instance, according to AHA Journals, it is estimated that 70% of people over 70 years old will develop CVD. 14.2% of adults aged 45 years and older reported having coronary heart disease (CHD), a stroke, or both. Thus increase in the number of aged population will expand the market growth.

High Cost of the Implantation Treatments Will Hamper the Market Growth

The high cost of the implantation treatments can hamper market growth. There is an increased cost for the treatments of surgeries related to implantation due to the increase in the complexity of the surgery. For instance, the average cost of pacemaker surgery in the US ranges between US$2,000- US$ 2,500.

COVID-19 Impact Analysis

The COVID-19 pandemic epidemic has had a significant influence on cardiovascular prosthetic devices, posing unprecedented challenges to many countries. The delayed surgical procedures and postponements of the surgeries, and the fear of patients approaching hospitals have shown the impact on the usage of cardiovascular prosthetic devices. This resulted in a significant decline in the cardiovascular prosthetic device growth during the COVID-19 pandemic.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the cardiovascular prosthetic device, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the cardiovascular prosthetic device growth over the forecast period.

Segment Analysis

The cardiovascular prosthetic device is segmented based on product type and end user.

The Implanted Heart Valve Segment Accounts for Approximately 23.8% of the Cardiovascular Prosthetic Device Share

An implanted heart valve is a one-way valve implanted into a person's heart to replace a heart valve that is not functioning properly. Due to the increase in the number of congenital heart valve diseases, implanted heart valve segment holds the highest market share.

According to texasheart.org, in the United States, surgeons perform about 106,000 heart valve operations each year. Each year approximately 40,000 babies are born in the United States with a congenital heart defect. Thus the above factors are influencing the segment to lead the market.

Geographical Analysis

Asia Pacific region accounted for Approximately 21.3% of the Market Share Owing to Technological Advancements

The rise in technological advancements and innovation of new devices is boosting the market share in Asia-Pacific region. A number of clinical trials and approvals have been taking place in this region in order to introduce a number of treatment methods and reduce mortality inthe region.

For instance, on 19 April 2022, Translumina announced the launch of the Vivo Isar dual-drug polymer-free coated stent in various international markets, including Europe and Asia-Pacific regions. Thus, the increase in technological advancements and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the cardiovascular prosthetic device market include: Abbott Laboratories, Boston Scientific Corporation, Lepu Medical Technology Co. Ltd, Medtronic Inc, Biotronik, Meril Life Sciences Pvt. Ltd, Pacetronix, MicroPort Scientific Corporation, Artivion, Inc, and JC Medical, Inc among others.

Why Purchase the Report?

To visualize the cardiovascular prosthetic device segmentation based on product type, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of cardiovascular prosthetic device market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The cardiovascular prosthetic device report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by End-User
3.3. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. An increase in the incidence of cardiovascular diseases
  - 4.1.1.2. Increase in the number of obese patients
- 4.1.2. Restraints
  - 4.1.2.1. Complications associated with the devices
- 4.1.3. Opportunity
  - 4.1.3.1. Increased number of treatments
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. ByProduct Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Pacemakers
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Implanted Heart Valves
7.4. Stents
7.5. Others

8. ByEnd User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinics/Cardiac Centers
8.4. Ambulatory Surgical Centers
8.5. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.5.1. U.S.
  - 9.2.5.2. Canada
  - 9.2.5.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.5.1. Germany
  - 9.3.5.2. U.K.
  - 9.3.5.3. France
  - 9.3.5.4. Spain
  - 9.3.5.5. Italy
  - 9.3.5.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.5.1. Brazil
  - 9.4.5.2. Argentina
  - 9.4.5.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.5.1. China
  - 9.5.5.2. India
  - 9.5.5.3. Japan

Australia

9.5.5.4. Rest of Asia-Pacific

9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Abbott Laboratories
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Artivion, Inc
11.3. Biotronik
11.4. MicroPort Scientific Corporation
11.5. JC Medical, Inc
11.6. Boston Scientific
11.7. Pacetronix
11.8. Meril Life Sciences Pvt. Ltd
11.9. Medtronic
11.10. Lepu Medical Technology Co. Ltd

LIST NOT EXHAUSTIVE

12. Appendix

12.1. About Us and Services
12.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

FAQ